System integrates glucose biosensor with an AI-driven platform to show how food, activity, stress, sleep affect the body in real time<\/p>\n<\/h3>\n
By Stephanie Brown HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Aug. 22, 2025 (HealthDay News) — The U.S. Food and Drug Administration has cleared the Signos Glucose Monitoring System, an over-the-counter glucose monitoring system for weight management.<\/p>\n
Signos integrates the Stelo by Dexcom glucose biosensor with an artificial intelligence-driven platform to show how food, activity, stress, sleep, and timing affect the body in real time — empowering people to make personalized, biology-backed health decisions.<\/p>\n
Key features of the monitoring system include personalized metabolic guidance that uses the body’s own signals and artificial intelligence-driven insights to help users improve sleep, manage weight, and lower chronic disease risk. The system translates real-time glucose fluctuations into simple, personalized recommendations for healthier daily habits and tracks and connects responses to meals, exercise, sleep, and stress.<\/p>\n
Customers can subscribe to Signos<\/a> with a three-month plan for $139 per month or a six-month plan for $129 per month. The company provides all necessary continuous glucose monitors for the chosen plan duration.<\/p>\n According to the U.S. Centers for Disease Control and Prevention<\/a>, 73.6 percent of U.S. adults are classified as having overweight or obesity. With the results of the Global Burden of Disease Study 2021<\/a> projecting diabetes diagnoses will reach 1.3 billion by 2050, the scale of the metabolic health crisis is rapidly accelerating.<\/p>\n “This is more than a product launch — it’s a mission,” Sharam Fouladgar-Mercer, CEO and founder of Signos, said in a statement. “Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn’t just about data; it’s about giving people ownership over their health and weight journeys in a way never before seen.”<\/p>\n